BioWisdom Announces Second Partner of Safety Intelligence Program
News Feb 19, 2008
BioWisdom Ltd has announced a three-year agreement with Johnson & Johnson Pharmaceutical Research & Development, Division of Janssen Pharmaceutica, NV (J&JPRD).
Under the terms of the agreement, J&JPRD will become the second partner for BioWisdom’s Safety Intelligence Program (SIP). The first partnership was formed with AstraZeneca. The financial details of the deal have not been disclosed.
The Safety Intelligence Program applies BioWisdom’s Sofia technology to deliver a specialist medical search system to support drug safety risk assessment at all stages of pharmaceutical R&D. Through the partnership, J&JPRD joins BioWisdom’s SIP board.
“We are delighted to have J&JPRD join our Safety Intelligence Program and look forward to working closely with safety assessment teams across the organization and affiliates” said Dr. Julie Barnes, Chief Scientific Officer of BioWisdom. “This second partnership is a testimony to the value that the pharmaceutical industry sees in our approach to drug safety and risk management.”
Dr Jack Reynolds, Chairman of the SIP Board said, “I am delighted to see the relationship between BioWisdom and J&JPRD established. I look forward to working with all partners on the SIP Board to advance the Safety Intelligence Program for the purpose of improving our understanding of many of the major recurring and potentially serious drug-induced adverse events.”
Novel Chemistry Technique Simplifies Late-Stage Modification of Drug CompoundsNews
Chemists at The Scripps Research Institute (TSRI) have invented a technique that overcomes a long-standing problem in organic chemistry and should streamline the process of discovery and development for many new drugs.READ MORE
Elpis BioMed Closes Funding Round to Commercialise Novel Technology Platform for Generating Human Cell TypesNews
New Cambridge spin-out company commercialises disruptive technology that enables rapid generation of pure and consistent batches of human cell types. Geographically diversified, top-tier investor team includes key industry leaders to support early company development.READ MORE